Recro To Report Financial Results for Second Quarter 2021 on August 9, 2021
02 août 2021 16h05 HE
|
Recro Pharma, Inc.
EXTON, Pa., Aug. 02, 2021 (GLOBE NEWSWIRE) -- Recro Pharma, Inc. (“Recro”; NASDAQ: REPH), a contract development and manufacturing organization (CDMO) dedicated to solving complex formulation and...
Recro Appoints Erica Raether as Vice President of People, Culture and ESG
20 juil. 2021 07h00 HE
|
Recro Pharma, Inc.
EXTON, Pa., July 20, 2021 (GLOBE NEWSWIRE) -- Recro Pharma, Inc. (“Recro”; NASDAQ: REPH), a contract development and manufacturing organization (CDMO) dedicated to solving complex formulation and...
Recro Enters Development and Manufacturing Agreement With New Client
13 juil. 2021 07h00 HE
|
Recro Pharma, Inc.
GAINESVILLE, Ga., July 13, 2021 (GLOBE NEWSWIRE) -- Recro Pharma, Inc. (“Recro”; NASDAQ: REPH), a contract development and manufacturing organization (CDMO) dedicated to solving complex formulation...
Recro Reports Inducement Grants for New Staff
07 juil. 2021 07h00 HE
|
Recro Pharma, Inc.
EXTON, Pa., July 07, 2021 (GLOBE NEWSWIRE) -- Recro Pharma, Inc. (“Recro”; NASDAQ: REPH), a contract development and manufacturing organization (CDMO) dedicated to solving complex formulation and...
Recro Appoints Laura L. Parks, Ph.D. to Board of Directors
16 juin 2021 07h00 HE
|
Recro Pharma, Inc.
EXTON, Pa., June 16, 2021 (GLOBE NEWSWIRE) -- Recro Pharma, Inc. (“Recro”; NASDAQ: REPH), a contract development and manufacturing organization (CDMO) dedicated to solving complex formulation and...
Recro Expands Capabilities for Growing Clinical Trial Services (CTS) Offerings
02 juin 2021 07h00 HE
|
Recro Pharma, Inc.
GAINESVILLE, Ga., June 02, 2021 (GLOBE NEWSWIRE) -- Recro Pharma, Inc. (“Recro”; NASDAQ: REPH), a contract development and manufacturing organization (CDMO) dedicated to solving complex formulation...
Recro Enters Development Agreement With Astex Pharmaceuticals
18 mai 2021 07h00 HE
|
Recro Pharma, Inc.
EXTON, Pa., May 18, 2021 (GLOBE NEWSWIRE) -- Recro Pharma, Inc. (“Recro”; NASD: REPH), a contract development and manufacturing organization (CDMO) dedicated to solving complex formulation and...
Recro Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters’ Option to Purchase Additional Shares
14 mai 2021 09h15 HE
|
Recro Pharma, Inc.
Underwriters’ Full Exercise of Option Brings Gross Proceeds to $34.5 Million EXTON, Pa., May 14, 2021 (GLOBE NEWSWIRE) -- Recro Pharma, Inc. (“Recro”; NASD:REPH), a contract development and...
Recro Announces Pricing of $30.0 Million Public Offering of Common Stock
12 mai 2021 08h30 HE
|
Recro Pharma, Inc.
EXTON, Pa., May 12, 2021 (GLOBE NEWSWIRE) -- Recro Pharma, Inc. (“Recro”; NASD:REPH), a contract development and manufacturing organization (CDMO) dedicated to solving complex formulation and...
Recro Announces Proposed Public Offering of Common Stock
11 mai 2021 16h30 HE
|
Recro Pharma, Inc.
EXTON, Pa., May 11, 2021 (GLOBE NEWSWIRE) -- Recro Pharma, Inc. (“Recro”; NASD:REPH), a contract development and manufacturing organization (CDMO) dedicated to solving complex formulation and...